Tyra Bioscience (TYRA) AI Stock Analysis

• Market Cap: $1.54B
• Dividend Yield: N/A
• Average Volume (3M): 370.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: N/A
• EPS Growth: -17.01%
• Country: US
• Employees: 60
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 53,372,097
• 10 Day Avg. Volume: 580,167
• 30 Day Avg. Volume: 370,944
• PEG Ratio: 1.35
• Price to Book (P/B): 2.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.29
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -10.57K
• Enterprise Value/Ebitda: -12.09
• 1Y Price Target: $33.75
• Price Target Upside: 17.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $30.00 ▲(4.28% Upside)

The score is held back mainly by weak financial performance (pre-revenue with rising losses and accelerating cash burn despite a low-debt balance sheet). Offsetting that, the technical setup is strong with clear trend strength, while valuation remains challenged due to negative earnings and no dividend support.

Positive Factors

Low leverage / balance-sheet strength

Very low debt reduces financial fragility and preserves optionality for multi-year clinical development. With minimal leverage the company can prioritize R&D and partner negotiations without immediate solvency pressure, improving strategic flexibility during long trial cycles.

Precision FGFR discovery platform

A computational, structure-based approach to FGFR-targeted small molecules is a durable competitive advantage: it can accelerate lead design, enable rational resistance management, and create hard-to-replicate IP, improving probability of differentiated clinical assets over the medium term.

Experienced oncology operations hire

Adding a COO with senior oncology and pharma experience strengthens operational and clinical development capabilities. Seasoned leadership can improve trial execution, regulatory strategy, and partner engagement — materially enhancing commercialization readiness over quarters.

Negative Factors

Pre-revenue with widening net losses

Sustained, growing operating losses without product revenue prolong dependence on financing. Continued negative earnings deplete equity, increase dilution risk, and pressure R&D prioritization, which can materially constrain strategic choices over the next several funding cycles.

Accelerating negative cash flow / burn

Worsening operating cash outflows drive near-term funding needs; reliance on equity raises or partnerships increases dilution uncertainty. Persistent negative free cash flow limits reinvestment options and elevates execution risk for multi-year clinical programs.

Concentrated FGFR-only pipeline risk

A highly focused FGFR-only pipeline magnifies binary clinical and regulatory outcomes: failure or delay of lead candidates would disproportionately affect company prospects. Limited program diversification raises long-term revenue and pipeline resilience concerns.

Tyra Bioscience Business Overview & Revenue Model

Company Description

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

How the Company Makes Money

Tyra Bioscience makes money primarily through its research and development activities in oncology therapeutics, which are aimed at bringing novel cancer treatments to market. The company generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on product sales if the drugs are successfully commercialized. Additionally, Tyra Bioscience may secure funding through grants and government programs focused on advancing cancer research. As its drugs progress through clinical trials and potentially receive regulatory approval, the company could also earn revenue from direct sales or licensing agreements.

Tyra Bioscience Financial Statement Overview

Summary

Balance sheet is a key strength (very low leverage), but the company is still pre-revenue with widening net losses and accelerating cash burn (negative operating cash flow and free cash flow), raising ongoing funding/dilution risk.

Income Statement

TYRA remains a pre-revenue biotechnology company, with $0 revenue across annual periods and in TTM (Trailing-Twelve-Months). Losses have widened meaningfully over time, with net loss increasing from about $26.3M (2021) to $86.5M (2024) and $111.7M in TTM (Trailing-Twelve-Months), indicating a rising cost base. Gross profit is slightly negative in TTM (Trailing-Twelve-Months), and profitability is deeply negative overall—offset only by the strategic positive that the company appears funded to operate despite the lack of revenue.

Balance Sheet

The balance sheet is a relative strength. Leverage is very low, with debt-to-equity around ~0.02 in both 2024 and TTM (Trailing-Twelve-Months), which reduces financial risk. However, equity has declined from $343.2M (2024) to $280.5M in TTM (Trailing-Twelve-Months), consistent with ongoing losses and cash burn, and returns on equity are negative in recent periods—signaling continued value dilution risk if losses persist.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative, including about -$69.8M operating cash flow (2024) and -$91.1M in TTM (Trailing-Twelve-Months). The burn rate has accelerated versus prior years (e.g., roughly -$50M operating cash flow in 2022–2023). A positive note is that free cash flow is broadly in line with net loss (free cash flow to net income near ~1), suggesting losses are not materially worse than cash usage, but the overall trajectory points to increased funding needs without revenue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-140.00K	0.00	0.00	0.00	0.00	-47.00K
EBITDA	-122.36M	-103.66M	-79.59M	-58.63M	-26.15M	-9.25M
Net Income	-111.68M	-86.48M	-69.13M	-55.33M	-26.29M	-9.31M
Balance Sheet
Total Assets	301.85M	363.56M	225.86M	266.18M	306.70M	16.01M
Cash, Cash Equivalents and Short-Term Investments	274.92M	341.44M	203.47M	251.21M	302.18M	15.22M
Total Debt	5.92M	6.22M	6.50M	2.62M	1.18M	142.00K
Total Liabilities	21.34M	20.41M	21.59M	8.35M	4.96M	29.65M
Stockholders Equity	280.51M	343.15M	204.26M	257.83M	301.74M	-13.64M
Cash Flow
Free Cash Flow	-91.20M	-70.44M	-50.91M	-50.84M	-24.41M	-8.07M
Operating Cash Flow	-91.11M	-69.77M	-50.14M	-50.28M	-23.75M	-7.76M
Investing Cash Flow	45.04M	-98.40M	-144.60M	-559.00K	-645.00K	-312.00K
Financing Cash Flow	4.12M	202.14M	1.54M	632.00K	311.35M	23.43M

Tyra Bioscience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 28.77 is above the 20-day moving average (MA) of 27.14, above the 50-day MA of 22.59, and above the 200-day MA of 14.00, indicating a bullish trend. The MACD of 1.92 indicates Positive momentum. The RSI at 67.17 is Neutral, neither overbought nor oversold. The STOCH value of 68.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.

Tyra Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TERN	61 Neutral	$3.89B	-35.47	-29.12%	―	―	12.45%
TYRA	57 Neutral	$1.54B	-15.31	-34.75%	―	―	-17.01%
KALV	57 Neutral	$737.98M	-3.65	―	―	―	-13.14%
NRIX	54 Neutral	$1.95B	-6.48	-65.35%	―	48.32%	-1.91%
PVLA	52 Neutral	$1.18B	-7.91	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GOSS	47 Neutral	$583.27M	-3.67	―	―	-58.17%	-116.24%

Tyra Bioscience Corporate Events

Tyra Bioscience Appoints Bhavesh Ashar as COO

Tyra Biosciences announced the appointment of Bhavesh Ashar as Chief Operating Officer, effective December 1, 2025, succeeding Daniel Bensen who will become the Chief Discovery Officer. Mr. Ashar brings extensive experience in oncology from his previous roles at SpringWorks Therapeutics, Bayer, and Sanofi Genzyme. His employment agreement includes a base salary of $550,000, stock options, and severance benefits, indicating a strategic move to strengthen the company’s executive team and potentially enhance its market position.

The most recent analyst rating on (TYRA) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.